The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic for 3 targeted therapies: alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.
The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic for 3 targeted therapies: alpelisib (Piqray) in advanced or metastatic breast cancer, rucaparib (Rubraca) in advanced ovarian cancer, and alectinib (Alecensa) in a specific type of metastatic non–small cell lung cancer (NSCLC).1
The regulatory agency also gave the green light to a label expansion for the diagnostic to report additional select copy number alterations and genomic rearrangements, according to an announcement from Foundation Medicine, Inc.
“FoundationOne Liquid CDx offers oncologists an important and minimally invasive tool to consider when making treatment decisions for their patients, regardless of the type of cancer they have,” Brian Alexander, MD, MPH, chief medical officer at Foundation Medicine, stated in a press release. “These 3 additional companion diagnostic claims expand the test’s clinical utility into breast and ovarian cancer, demonstrating our commitment to bringing precision medicine to more patients, and we plan to continue working with our biopharma partners to increase that reach.”
FoundationOne Liquid CDx is a companion diagnostic that evaluates guideline-recommended genes from a blood sample; the test is capable of evaluating over 300 genes.2 The blood-based biopsy also reports blood tumor mutational burden, microsatellite instability, and tumor fraction values. The goal of the test is to help inform treatment approaches and predict benefit of certain targeted therapies in patients across several cancer indications.
The regulatory approval expands the assay’s indications to include the following targeted treatments:
Previously, in August 2020, the FoundationOne Liquid CDx was approved by the FDA for all solid tumors with multiple companion diagnostic indications. The decision was based on data from analytical and clinical validation studies that collected over 7500 samples and 30,000 unique variants spanning over 30 tumor types. The test was shown to have high sensitivity and specificity, even at the low allele frequencies observed in the blood samples that were collected for analysis.3,4